JP7564110B2 - 化合物の凝縮物に関連する特性を特性評価する方法およびその使用 - Google Patents

化合物の凝縮物に関連する特性を特性評価する方法およびその使用 Download PDF

Info

Publication number
JP7564110B2
JP7564110B2 JP2021544451A JP2021544451A JP7564110B2 JP 7564110 B2 JP7564110 B2 JP 7564110B2 JP 2021544451 A JP2021544451 A JP 2021544451A JP 2021544451 A JP2021544451 A JP 2021544451A JP 7564110 B2 JP7564110 B2 JP 7564110B2
Authority
JP
Japan
Prior art keywords
condensate
compound
test compound
target
partitioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519523A (ja
JP2022519523A5 (https=
Inventor
ブルース アーロン ビューテル，
ピーター ジェフリー ダンドライカー，
スティーブン ポール ヘイル，
マーク アンドリュー ムルコ，
エドガー エリック ボチェク，
マテウス ミタシュ，
ダイアナ マリア ミトレア，
Original Assignee
デューポイント セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デューポイント セラピューティクス， インコーポレイテッド filed Critical デューポイント セラピューティクス， インコーポレイテッド
Publication of JP2022519523A publication Critical patent/JP2022519523A/ja
Publication of JP2022519523A5 publication Critical patent/JP2022519523A5/ja
Priority to JP2024167248A priority Critical patent/JP2024178423A/ja
Application granted granted Critical
Publication of JP7564110B2 publication Critical patent/JP7564110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021544451A 2019-02-08 2020-02-07 化合物の凝縮物に関連する特性を特性評価する方法およびその使用 Active JP7564110B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024167248A JP2024178423A (ja) 2019-02-08 2024-09-26 化合物の凝縮物に関連する特性を特性評価する方法およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962803365P 2019-02-08 2019-02-08
US62/803,365 2019-02-08
US201962866526P 2019-06-25 2019-06-25
US62/866,526 2019-06-25
PCT/US2020/017333 WO2020163795A1 (en) 2019-02-08 2020-02-07 Methods of characterizing condensate-associated characteristics of compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024167248A Division JP2024178423A (ja) 2019-02-08 2024-09-26 化合物の凝縮物に関連する特性を特性評価する方法およびその使用

Publications (3)

Publication Number Publication Date
JP2022519523A JP2022519523A (ja) 2022-03-24
JP2022519523A5 JP2022519523A5 (https=) 2023-02-15
JP7564110B2 true JP7564110B2 (ja) 2024-10-08

Family

ID=69771186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544451A Active JP7564110B2 (ja) 2019-02-08 2020-02-07 化合物の凝縮物に関連する特性を特性評価する方法およびその使用
JP2024167248A Pending JP2024178423A (ja) 2019-02-08 2024-09-26 化合物の凝縮物に関連する特性を特性評価する方法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024167248A Pending JP2024178423A (ja) 2019-02-08 2024-09-26 化合物の凝縮物に関連する特性を特性評価する方法およびその使用

Country Status (10)

Country Link
US (3) US11493519B2 (https=)
EP (1) EP3921650A1 (https=)
JP (2) JP7564110B2 (https=)
KR (1) KR20210124374A (https=)
CN (1) CN113424064B (https=)
AU (1) AU2020219368A1 (https=)
CA (1) CA3127237A1 (https=)
IL (1) IL285117A (https=)
SG (1) SG11202106690QA (https=)
WO (1) WO2020163795A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3921650A1 (en) 2019-02-08 2021-12-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
WO2022187202A1 (en) * 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. New condensate paradigms
EP4220159A1 (en) * 2022-01-27 2023-08-02 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
EP4063857A1 (en) * 2021-03-26 2022-09-28 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
EP4314815A1 (en) * 2021-03-26 2024-02-07 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Drug discovery assay to screen for compounds
CA3244504A1 (en) * 2021-12-31 2023-07-06 Laboratory Corporation Of America Holdings METHODS AND SYSTEMS FOR HYDROPHILIC PHASE EXTRACTION
KR20250022285A (ko) 2023-08-07 2025-02-17 포항공과대학교 산학협력단 액체-액체 상분리를 통한 scotin 프롤린-풍부 도메인 생체분자 응축물 및 그의 응용
WO2025050003A1 (en) * 2023-09-01 2025-03-06 Transition Bio, Inc. High-throughput condensate modulator screen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068341A1 (en) 2015-10-19 2017-04-27 Oxford University Innovation Ltd. Biomolecule separation and modification

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239907T1 (de) 1999-02-26 2003-05-15 Cellomics Inc Ein system für zellbasierte reihenuntersuchungen
WO2002038734A2 (en) 2000-11-13 2002-05-16 Cistem Molecular Corporation Methods for determining the biological effects of compounds on gene expression
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
JP4200100B2 (ja) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
US20170198046A1 (en) 2002-02-13 2017-07-13 Technion Research & Development Foundation Limited Compositions capable of specifically binding particular human antigen presenting molecule/ antigen complexes and uses thereof
WO2004029247A1 (en) 2002-09-26 2004-04-08 Centre For Translational Research In Cancer Nuclear receptor transcriptional corepressor and uses thereof
US20070178537A1 (en) 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
CN102989009B (zh) 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
WO2005099745A2 (en) 2004-04-13 2005-10-27 Uab Research Foundation Gcp-170 fusion proteins and uses thereof
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
WO2006070941A1 (ja) 2004-12-28 2006-07-06 Tokyo University Of Science 蛍光分子プローブを用いた新規薬剤スクリーニング方法
US20070214509A1 (en) 2005-12-23 2007-09-13 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
CA2634821C (en) 2005-12-23 2016-05-03 Andrew Emili Method for the identification of macromolecule targets of analytes
ES2338392B1 (es) 2006-08-18 2011-02-28 Universidad De Salamanca Metodo para la identificacion de signos de disfuncion neuronal pre-neurodegenerativos.
US9470683B2 (en) 2010-01-29 2016-10-18 Ge Healthcare Bio-Sciences Ab Method for determination of aggregates
US20130109737A1 (en) 2010-02-09 2013-05-02 Richard A. Young Mediator and cohesin connect gene expression and chromatin architecture
US8563705B2 (en) 2010-05-12 2013-10-22 Mayo Foundation For Medical Education And Research Ribonucleic acid binding motif protein 20 sequence variants
WO2012006551A2 (en) 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
EP2630154A1 (en) 2010-10-20 2013-08-28 F.Hoffmann-La Roche Ag Methods and compositions for modulating the wnt pathway
WO2012162249A1 (en) 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions
US20140349938A1 (en) 2011-06-03 2014-11-27 President And Fellows Of Harvard College Methods of diagnosing and treating amyotrophic lateral sclerosis
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
US20150045330A1 (en) 2012-01-17 2015-02-12 Kyoto University Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor
JP6340366B2 (ja) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 運動ニューロン疾患を診断および処置する方法
ES2762326T5 (es) 2012-10-15 2023-04-27 Ionis Pharmaceuticals Inc Métodos para modular la expresión de C9ORF72
EP2912178B1 (en) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
HK1220233A1 (zh) 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
KR101591265B1 (ko) 2014-03-28 2016-02-03 한남대학교 산학협력단 퇴행성 신경계 질환 치료제 스크리닝 방법
US20170233762A1 (en) 2014-09-29 2017-08-17 The Regents Of The University Of California Scaffold rnas
KR20170092543A (ko) 2014-11-07 2017-08-11 톨레로 파마수티컬스, 인크. 슈퍼-인핸서 부위에서 전사 조절을 표적화하는 방법
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3242938B1 (en) 2015-01-09 2020-01-08 Bio-Rad Laboratories, Inc. Detection of genome editing
KR101671020B1 (ko) 2015-04-10 2016-11-02 충북대학교 산학협력단 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물
EP3362564B1 (en) 2015-10-14 2020-07-01 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
KR102346785B1 (ko) 2016-05-30 2022-01-04 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 공동-분획에 의한 리간드 식별
US10533167B2 (en) 2016-06-09 2020-01-14 The Trustees Of Princeton University Optogenetic tool for rapid and reversible clustering of proteins
JP2019523242A (ja) 2016-07-01 2019-08-22 アラーキス セラピューティクス， インコーポレイテッド Ｒｎａ機能をモジュレートするための化合物および方法
ES2973215T3 (es) 2016-09-02 2024-06-19 Univ Keio Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento
JP2018050605A (ja) 2016-09-30 2018-04-05 学校法人慶應義塾 筋萎縮性側索硬化症、及び前頭側頭型認知症の病態誘導人工合成遺伝子、及びこれを用いた病態モデル
US10303979B2 (en) 2016-11-16 2019-05-28 Phenomic Ai Inc. System and method for classifying and segmenting microscopy images with deep multiple instance learning
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
WO2018158160A1 (en) 2017-02-28 2018-09-07 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
US10538756B2 (en) 2017-03-06 2020-01-21 The Trustees Of Princeton University Disordered protein-based seeds for molecular clustering
WO2018170794A1 (en) 2017-03-22 2018-09-27 Tsinghua University Mutant fus model for als
US11492617B2 (en) 2017-08-08 2022-11-08 Ionis Pharmaceuticals, Inc Compositions and methods for modulation of protein aggregation
US10526380B2 (en) 2017-10-26 2020-01-07 St. Jude Children's Research Hospital Fusion protein and nucleic acid molecule for light-dependent stress granule assembly
WO2019109017A1 (en) 2017-12-01 2019-06-06 The Trustees Of Princeton University Light-responsive fusion proteins for controlling binding to targets
GB201803724D0 (en) 2018-03-08 2018-04-25 Cambridge Entpr Ltd Methods
CA3094974A1 (en) 2018-03-23 2019-09-26 Whitehead Institute For Biomedical Research Methods and assays for modulating gene transcription by modulating condensates
JP6624468B2 (ja) 2018-04-18 2019-12-25 国立大学法人滋賀医科大学 Ｔｄｐ−４３の凝集体が蓄積する疾患を治療及び／又は予防するための化合物のスクリーニング方法
US12521412B2 (en) 2018-08-16 2026-01-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Nucleic acids and nucleic acid analogs for treating, preventing, and disrupting pathological polynucleotide-binding protein inclusions
CN113196055B (zh) 2018-10-15 2025-06-27 马克斯·普朗克科学促进协会 用于治疗疾病的化合物及其筛选方法
EP3921650A1 (en) 2019-02-08 2021-12-15 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CA3140651A1 (en) 2019-05-15 2020-11-19 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN114667451A (zh) 2019-09-18 2022-06-24 露点治疗公司 用于鉴定调节与RBM20聚集体和/或Rbm20多肽相关的一种或多种特征的化合物的组合物、系统以及方法
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
US20230314443A1 (en) 2020-08-12 2023-10-05 Dewpoint Therapeutics, Inc. Methods of identifying interactions of a compound and a condensate, or a component thereof, and uses thereof
WO2022187202A1 (en) 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. New condensate paradigms
WO2022187225A1 (en) 2021-03-02 2022-09-09 Dewpoint Therapeutics, Inc. Methods of identifying a condensate phenotype and uses thereof
US20240375024A1 (en) 2021-08-20 2024-11-14 Dewpoint Therapeutics, Inc. Methods of isolating a composition comprising a target molecule
US20260043792A1 (en) 2022-08-03 2026-02-12 Dewpoint Therapeutics, Inc. Methods of identifying selective condensate modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068341A1 (en) 2015-10-19 2017-04-27 Oxford University Innovation Ltd. Biomolecule separation and modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Banani Salman F., et al.,，Compositional Control of Phase-Separated Cellular Bodies，Cell，Cell Press，2016年06月30日，166(3)，651-663，https://doi.org/10.1016/j.cell.2016.06.010，ISR D1
Eric J Lanni, et al.,，Mass spectrometry imaging and profiling of single cells，Journal of Proteomics，Elsevier，2012年08月01日，75(16)，5036-5051，https://doi.org/10.1016/j.jprot.2012.03.017，ISR D2

Also Published As

Publication number Publication date
CN113424064A (zh) 2021-09-21
AU2020219368A1 (en) 2021-07-15
CN113424064B (zh) 2025-03-04
US12174198B2 (en) 2024-12-24
EP3921650A1 (en) 2021-12-15
US20200284801A1 (en) 2020-09-10
KR20210124374A (ko) 2021-10-14
US11493519B2 (en) 2022-11-08
US20230176067A1 (en) 2023-06-08
SG11202106690QA (en) 2021-07-29
JP2022519523A (ja) 2022-03-24
CA3127237A1 (en) 2020-08-13
WO2020163795A1 (en) 2020-08-13
IL285117A (en) 2021-09-30
US20250298031A1 (en) 2025-09-25
JP2024178423A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
JP7564110B2 (ja) 化合物の凝縮物に関連する特性を特性評価する方法およびその使用
US20230314443A1 (en) Methods of identifying interactions of a compound and a condensate, or a component thereof, and uses thereof
Zhang et al. Subcellular peptide localization in single identified neurons by capillary microsampling mass spectrometry
US10159952B2 (en) Method for lysing a single cell in a solid tissue
Liu et al. AANL (Agrocybe aegerita lectin 2) is a new facile tool to probe for O-GlcNAcylation
CN114729941A (zh) 筛选凝聚物相关特异性的方法及其用途
Pfeiffer et al. Selective immunocapture reveals neoplastic human mast cells secrete distinct microvesicle‐and exosome‐like populations of KIT‐containing extracellular vesicles
Engmann et al. Neuronal subtype-specific growth cone and soma purification from mammalian CNS via fractionation and fluorescent sorting for subcellular analyses and spatial mapping of local transcriptomes and proteomes
Tian Exploring intercellular signaling by proteomic approaches
Cao et al. Proteomic profiling of concurrently isolated primary microvascular endothelial cells, pericytes, and vascular smooth muscle cells from adult mouse heart
Krispin et al. Organellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons
Gandhimathi et al. Super‐resolution microscopy reveals focal organization of ER‐associated Y‐complexes in mitosis
Coumans et al. Proteomic and microscopic strategies towards the analysis of the cytoskeletal networks in major neuropsychiatric disorders
Colucci-D’Amato et al. Quantitative neuroproteomics: classical and novel tools for studying neural differentiation and function
Popova et al. NCBP2-AS2 is a mitochondrial microprotein, regulates energy metabolism and neurogenesis, and is downregulated in Alzheimer’s disease
Yigit et al. Loss of Eml1 alters microtubule-associated protein networks in mouse brain heterotopia
Hamilton et al. ASCL2 is a key regulator of the proliferation–differentiation equilibrium in the esophageal epithelium
CN121620701A (zh) β-连环蛋白贮库检测和调节测定
Ganguly et al. Mechanistic Determinants of Slow Axonal Transport and Presynaptic Targeting of Clathrin Packets
Hildebrandt Elucidating mechanisms of RNA localization mediated by modular domains of RNA binding proteins
Lundberg EVALUATING THE ROLE OF ALZHEIMER’S DISEASE LINKED APP MUTATIONS ON CORTICAL DEVELOPMENT
Kao The Proteomic Architecture of Human Fetal Neurogenesis
Nomellini et al. Modern techniques for protein assessment
Wu Quantitative chemical proteomics for cancer characterization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240926

R150 Certificate of patent or registration of utility model

Ref document number: 7564110

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02